عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

Elon Musk Briefly Loses Title as World’s Richest Person to LVMH's Arnault  

Elon Musk arrives at the In America: An Anthology of Fashion themed Met Gala at the Metropolitan Museum of Art in New York City, New York, US, May 2, 2022. (Reuters)
Elon Musk arrives at the In America: An Anthology of Fashion themed Met Gala at the Metropolitan Museum of Art in New York City, New York, US, May 2, 2022. (Reuters)
TT
TT

Elon Musk Briefly Loses Title as World’s Richest Person to LVMH's Arnault  

Elon Musk arrives at the In America: An Anthology of Fashion themed Met Gala at the Metropolitan Museum of Art in New York City, New York, US, May 2, 2022. (Reuters)
Elon Musk arrives at the In America: An Anthology of Fashion themed Met Gala at the Metropolitan Museum of Art in New York City, New York, US, May 2, 2022. (Reuters)

Twitter owner and Tesla boss Elon Musk briefly lost his title as the world's richest person on Wednesday, according to Forbes, following a steep drop in the value of his stake in the electric-car maker and a $44 billion bet on the social media firm. 

Bernard Arnault, the chief executive of luxury brand Louis Vuitton's parent company LVMH, and his family briefly took the title as the world's richest, but were back at No. 2 with a personal wealth of $185.3 billion, according to Forbes. 

Musk, who has held the top spot on the Forbes list since September 2021, has a net worth of $185.7 billion. Musk took over the title from Amazon.com founder Jeff Bezos. 

Tesla shares, which have lost more than 47% in value since Musk made his offer to buy Twitter earlier this year, were down 2.7%. 

Musk's net worth dropped below $200 billion earlier on Nov. 8 as investors dumped Tesla's shares on worries the top executive and largest shareholder of the world's most valuable electric-vehicle maker is more preoccupied with Twitter. 

Tesla has lost nearly half its market value and Musk's net worth has dropped by about $70 billion since he bid for Twitter in April. Musk closed the deal for Twitter in October with $13 billion in loans and a $33.5 billion equity commitment. 

Besides Tesla, Musk also heads rocket company SpaceX and Neuralink, a startup that is developing ultra-high bandwidth brain-machine interfaces to connect the human brain to computers. 

Most Viewed

 
 
Varieties

Rwanda and WHO Declare End of Marburg Outbreak after No New Cases Reported

In this Oct. 8, 2014 photo, a medical worker from the Infection Prevention and Control unit wearing full protective equipment carries a meal to an isolation tent housing a man being quarantined after coming into contact in Uganda with a carrier of the Marburg Virus, at the Kenyatta National Hospital in Nairobi, Kenya. (AP)
In this Oct. 8, 2014 photo, a medical worker from the Infection Prevention and Control unit wearing full protective equipment carries a meal to an isolation tent housing a man being quarantined after coming into contact in Uganda with a carrier of the Marburg Virus, at the Kenyatta National Hospital in Nairobi, Kenya. (AP)
TT
TT

Rwanda and WHO Declare End of Marburg Outbreak after No New Cases Reported

In this Oct. 8, 2014 photo, a medical worker from the Infection Prevention and Control unit wearing full protective equipment carries a meal to an isolation tent housing a man being quarantined after coming into contact in Uganda with a carrier of the Marburg Virus, at the Kenyatta National Hospital in Nairobi, Kenya. (AP)
In this Oct. 8, 2014 photo, a medical worker from the Infection Prevention and Control unit wearing full protective equipment carries a meal to an isolation tent housing a man being quarantined after coming into contact in Uganda with a carrier of the Marburg Virus, at the Kenyatta National Hospital in Nairobi, Kenya. (AP)

The World Health Organization and the Rwandan government on Friday declared the outbreak in Rwanda of the Ebola-like Marburg fever over after no new cases were registered in recent weeks.

The country first declared the outbreak on Sept. 27 and reported a total of 15 deaths and 66 cases, with the majority of those affected healthcare workers who handled the first patients.

Without treatment, Marburg can be fatal in up to 88% of people who fall ill with the disease. Symptoms include fever, muscle pains, diarrhea, vomiting and, in some cases, death through extreme blood loss.

There is no authorized vaccine or treatment for Marburg, though Rwanda received hundreds of doses of a vaccine under trial in October.

An outbreak is considered over after 42 days — two 21-day incubation cycles of the virus — elapsed without registering new cases and all existing cases test negative.

Rwanda discharged the last Marburg patient on Nov. 8 and had reported no new confirmed cases since Oct. 30.

However, WHO officials and Rwanda's Health Minister Dr. Sabin Nzanzimana on Friday said risks remain and that people should stay vigilant.

“We believe it’s not completely over because we still face risks, especially from bats. We are continuing to build new strategies, form new health teams, and deploy advanced technologies to track their movements, understand their behavior, and monitor who is interacting with them,” the minister announced during a press conference in the capital, Kigali.

Like Ebola, the Marburg virus is believed to originate in fruit bats and spreads between people through close contact with the bodily fluids of infected individuals or with surfaces, such as contaminated bed sheets.

“I thank the government of Rwanda, its leadership and Rwandans in general for the strong response to achieve this success but the battle continues,” said the WHO representative in Rwanda, Dr. Brain Chirombo.

Marburg outbreaks and individual cases have in the past been recorded in Tanzania, Equatorial Guinea, Angola, Congo, Kenya, South Africa, Uganda and Ghana.

The virus was first identified in 1967 after it caused simultaneous outbreaks of disease in laboratories in the German city of Marburg and in Belgrade in the former Yugoslavia. Seven people died after being exposed to the virus while conducting research on monkeys.